News & analysis on the clinical development and manufacture of large molecule drugs
Redpin Therapeutics: David Bleakman
By Ben Hargreaves
- Last updated on
A veteran of Eli Lilly has taken up a position at Redpin Therapeutics as its CSO.
David Bleakman spent over 25 years with Eli Lilly, finishing his career at the company as VP and CSO for neuroscience. After a six-month break from the pharma industry, he joined Redpin.
The New York-based company is focused on developing treatments for severe neurological disorders, using chemogenetics that enables the targeted regulation of neuronal cell activity in the brain through a gene therapy approach. It was founded in 2017, supported through the financial backing of Arkin Bio Ventures, New York Ventures and Alexandria Venture Investments
Elma Hawkins, CEO of Redpin, stated: “We are thrilled to welcome David to our team and look forward to leveraging his expansive expertise in CNS drug discovery and development to guide the advancement of our technology platforms and pipeline.”
Bleakman explained the appeal of joining the newly-formed company, saying, “I was particularly drawn to the potentially broad applicability of Redpin’s technology and, hence, the opportunity to help many patients. Our technology can be used to address currently intractable disorders across disparate therapeutic areas.”